News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|February 11, 2017

Liver Cancer: What's On the Horizon?

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia: © stock.adobe.com.

Besremi Recognized by Updated Guidelines for Essential Thrombocythemia

January 28th 2026

Dr. Anne Peled

Breast Cancer Surgeon and Survivor Undergoes Nerve-Sparing Procedure

January 27th 2026

The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal tumors following progression.

FDA Grants Designation to Bezuclastinib Combo in Advanced GIST

January 27th 2026

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

January 27th 2026

Dr. Anne Peled

Two-Time Breast Cancer Survivor Shares Advice for Fellow Patients

ByDr. Anne Peled

January 27th 2026

Trending on CURE

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma

Two-Time Breast Cancer Survivor Shares Advice for Fellow Patients

FDA Grants Designation to Bezuclastinib Combo in Advanced GIST

Rethinking Medications at the End of Life for Patients With Advanced Cancer